OM Outset Medical, Inc.
Electromedical & Electrotherapeutic Apparatus · Nasdaq · SEC CIK 1484612 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY1.6%
TTM net income YoY19.0%
TTM EPS YoY67.5%
Revenue 3-yr CAGR-2.6%
Net income 3-yr CAGR—
Margins
Gross margin42.0%
Operating margin-51.2%
Net margin-58.3%
FCF margin-35.2%
EBITDA margin-48.8%
Returns
ROE-63.0%
ROA-28.0%
ROIC (approx.)-28.3%
Asset turnover0.48x
Leverage & solvency
Liabilities / assets63.8%
Debt / equity1.18x
Current ratio4.86x
Interest coverage-4.54x
Cash quality & payout
Operating cash flow / net income0.60x
Accruals ratio-11.3%
Payout ratio—
Capex / revenue0.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $119.48M | $113.69M | $130.38M | $115.38M | $102.60M |
| Cost of revenue | $72.72M | $75.12M | $101.38M | $97.54M | $94.99M |
| Gross profit | $46.75M | $38.56M | $29.00M | $17.83M | $7.61M |
| R&D expense | $21.23M | $38.40M | $57.31M | $48.85M | $36.74M |
| SG&A expense | $37.86M | $43.50M | $45.23M | $40.52M | $36.32M |
| Operating income | -$66.71M | -$113.38M | -$169.77M | -$161.02M | -$130.52M |
| Interest expense | $13.95M | $23.87M | $12.68M | $3.57M | $1.72M |
| Pretax income | -$80.94M | -$127.48M | -$172.27M | -$162.66M | -$131.74M |
| Income tax | $718,000 | $491,000 | $523,000 | $295,000 | $199,000 |
| Net income | -$81.65M | -$127.98M | -$172.80M | -$162.96M | -$131.94M |
| EBITDA | -$62.37M | -$107.65M | -$163.96M | -$155.85M | -$125.36M |
| EPS (basic) | -5.37 | -36.96 | -52.28 | -3.38 | -2.89 |
| EPS (diluted) | -5.37 | -36.96 | -52.28 | -3.38 | -2.89 |
| Weighted avg. shares (diluted) | 15,211 | 3,463 | 3,305 | 48,161 | 45,589 |
| Balance sheet | |||||
| Cash & equivalents | $35.01M | $124.01M | $68.51M | $73.22M | $182.35M |
| Short-term investments | $133.94M | $34.67M | $134.81M | $214.28M | $157.14M |
| Receivables | $28.33M | $35.62M | $32.98M | $28.07M | $25.60M |
| Inventory | $47.61M | $59.39M | $49.22M | $51.48M | $39.19M |
| Current assets | $250.88M | $258.22M | $291.22M | $373.64M | $409.80M |
| PP&E, net | $4.67M | $8.13M | $13.27M | $15.88M | $12.96M |
| Total assets | $264.50M | $275.80M | $313.80M | $400.12M | $463.46M |
| Current liabilities | $37.63M | $45.38M | $55.32M | $51.95M | $51.70M |
| Short-term debt | — | — | — | $4.75M | $0 |
| Long-term debt | $96.24M | $197.38M | $130.11M | $96.34M | $29.76M |
| Total debt | $96.24M | $197.38M | $130.11M | $101.09M | $29.76M |
| Total liabilities | $137.54M | $248.98M | $190.91M | $154.12M | $89.38M |
| Shareholders' equity | $126.95M | $26.82M | $122.89M | $245.99M | $374.08M |
| Net debt | $61.23M | $73.36M | $61.60M | $27.86M | -$152.59M |
| Shares outstanding | 18.17M | 3.53M | 50.32M | 48.47M | 47.24M |
| Cash flow statement | |||||
| Operating cash flow | -$46.33M | -$116.30M | -$131.37M | -$145.73M | -$130.26M |
| Capital expenditure | $798,000 | $912,000 | $3.44M | $8.32M | $3.11M |
| Free cash flow | -$47.12M | -$117.22M | -$134.81M | -$154.05M | -$133.37M |
| Investing cash flow | -$97.68M | $103.94M | $83.03M | -$66.30M | -$142.51M |
| Financing cash flow | $55.50M | $67.87M | $43.65M | $72.90M | $160.15M |
| Depreciation & amortization | $4.34M | $5.73M | $5.81M | $5.17M | $5.16M |
| Stock-based compensation | $15.62M | $29.36M | $38.63M | $27.20M | $17.45M |
Free plan shows the latest 5 periods; Pro shows all 8 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.